- June 05, 2023
Registered Dietician Natalie Smith on Yale Cancer Answers
- June 05, 2023Source: Al Jazeera Media View
Osimertinib significantly improves survival following surgery for patients with non-small cell lung cancer who are EGFR+ in the earliest stages
- June 05, 2023Source: Wall Street Journal
For Some Cancers, Less Treatment Is a Better Bet
- June 05, 2023Source: The Times
Lung cancer pill halves risk of death after surgery
- June 05, 2023Source: Daily Mail
New British lung cancer drug from AstraZeneca is hailed as a 'game changer' that can HALVE the risk of dying
- June 04, 2023
Profiles in Survivorship: Donna Vavrinec
- June 04, 2023
Study Shows Osimertinib Improves Survival Following Surgery for Non-Small Cell Lung Cancer
- June 04, 2023Source: The Guardian
Lung cancer pill cuts risk of death by half, says ‘thrilling’ study
- June 04, 2023Source: Cancer Network
Osimertinib Yields Improvement in Survival in Adjuvant EGFR+ NSCLC
- June 04, 2023Source: The Daily Upside
US Taps Chinese Drug Company Amid Chemotherapy Shortages
- June 04, 2023Source: HemeOnc Today
Osimertinib after surgery reduces risk for death by 51% in resected EGFR-mutant NSCLC
- June 04, 2023Source: STAT
‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug
- June 04, 2023Source: Wall Street Journal
Treatment Breakthrough for an Intractable Brain Cancer
- June 04, 2023Source: MedPage Today
New Standard in Operable EGFR-Positive Lung Cancer
- June 04, 2023Source: Survivor Net
Game-Changer: Tagrisso May Reduce Risk of Death by Half in Some Early-Stage Lung Cancer Patients, ‘Compelling’ New Data Shows
- June 03, 2023Source: The ASCO Post
Impact of Changing Opioid Prescription Landscape for Patients With Cancer
- June 03, 2023Source: HemeOnc Today
Surgeon general: Burnout has many health care workers ‘in crisis’
- June 02, 2023Source: NBC CT
Closer to Free Prepares for This Year's Ride
- June 02, 2023
Profiles in Survivorship: Bob Heffernan
- June 02, 2023Source: OncLive
Dr Zeidan on Imetelstat in Lower-risk MDS
Research and Education
In the fight against cancer, Yale has been at the forefront of understanding the fundamental mechanisms of cancer biology and in developing effective therapies for the treatment of cancer. Yale Cancer Center harnesses the resources of Yale School of Medicine and Yale New Haven Hospital to advance cancer research, prevention, and patient care, as well as community outreach and education.
Publications
828 Publications - June 30, 2021-July 1, 2022
213 High Impact Publications, including:
- 41 - Nature/Nature Speciality
- 21 - Clinical Cancer Research
- 19 - Journal for Immunotherapy of Cancer
- 14 - Journal of Clinical Oncology
- 11 - Science/Science Specialty
- 10 - Journal of National Cancer Institute
- 9 - JAMA/JAMA Oncology
- 7 - Journal of Thoracic Oncology
- 7 - New England Journal of Medicine
- 6 - Cancer Discovery
- 5 - Cell/Cell Specialty
- 4 - Molecular Cell
- 4 - Lancet/Lancet Oncology